Whatever Happened to Up-Front Equity?
Executive Summary
In the past, in-licensers of biotech products often turned to up-front equity purchases, rather than cash licensing payments, to help defray P&L costs of licensing. The partner received the same money to fund its research, the rationale went, and the licensee could book at least some of the payment as the acquisition of an asset, rather than an R&D expense. But as In Vivo amply demonstrates, that thinking is so 20th Century. While equity payments often made up more than half the total paid up front in biotech licensings throughout the 1990's, they've fallen to 25% or below, since 2002.
You may also be interested in...
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
QUOTED. 22 January 2021. Neil Moat.
The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage for mitral valve transcatheter edge-to-edge repair under a new coverage with evidence development policy. See what Neil Moat, chief medical officer for Abbott’s structural heart business, said about it here.
ICCR’s Growing Membership Ensures Diverse Cosmetics Regulatory Perspectives – PCPC
South Korea’s Ministry of Food and Drug Safety and Taiwan’s Food and Drug Administration will transition from ICCR observers to full members, joining regulatory authorities from the US, Europe, Japan, Canada and Brazil. PCPC’s Francine Lamoriello, EVP of global affairs, discusses.
Need a specific report? 1000+ reports available
Buy Reports